Inventiva’s is actively working on the newly discovered signaling pathway Hippo Pathway which has been shown to be involved in controlling cell proliferation and organ size. Our program seeks at identifying small molecules that bind to the Hippo downstream transcription factor TEAD and thus preventing its association with Yap and the activation of oncogenic pathways. 

YAP-TEAD inhibitors represent a promising and innovative therapeutic strategy to address unmet medical needs:

  • Targeting tumors where high nuclear YAP levels are observed
  • Enhancing efficacy and survival for patient with a broad range of BRAF-, STK11- and RAS-mutant tumors

This program has received research grants from the European Community Eurostars program and from the Agence Nationale de Recherche (ANR). Learn more

Primary Indications

  • Non-small cell lung cancer (NSCLC) harboring BRAF V600E, KRAS G12 or STK11 mutations
  • Ovarian serous tumors with STK11 allelic loss
  • Pancreatic cancer carrying oncogenic KRAS mutation
  • Rare pulmonary cancers